Nollet E, Algul S, Goebel M, Schlossarek S, van der Wel N, Jans J
J Mol Cell Cardiol Plus. 2025; 6():100050.
PMID: 39802622
PMC: 11708371.
DOI: 10.1016/j.jmccpl.2023.100050.
Gwak S, Seo J, Seo G, Oh J, Lee H, Kim K
J Korean Med Sci. 2025; 39(50):e313.
PMID: 39742874
PMC: 11685281.
DOI: 10.3346/jkms.2024.39.e313.
Lumish H, Sherrid M, Janssen P, Ferrari G, Hasegawa K, Castillero E
J Am Coll Cardiol. 2024; 84(20):1999-2011.
PMID: 39365226
PMC: 11817648.
DOI: 10.1016/j.jacc.2024.07.043.
Lynn M, Jimenez J, Castillo R, Vasquez C, Klass M, Baldo A
Circ Res. 2024; 135(10):974-989.
PMID: 39328062
PMC: 11502267.
DOI: 10.1161/CIRCRESAHA.124.325223.
Rosamilia M, Markunas A, Kishnani P, Landstrom A
JACC Adv. 2024; 3(2).
PMID: 38464909
PMC: 10922016.
DOI: 10.1016/j.jacadv.2023.100767.
[Hypertrophic septal cardiomyopathy, the great simulator].
Forero S, Moreno N
Arch Peru Cardiol Cir Cardiovasc. 2023; 2(4):274-278.
PMID: 37727664
PMC: 10506570.
DOI: 10.47487/apcyccv.v2i4.171.
Clinical and Genetic Screening for Hypertrophic Cardiomyopathy in Paediatric Relatives: Changing Paradigms in Clinical Practice.
Lawley C, Kaski J
J Clin Med. 2023; 12(8).
PMID: 37109125
PMC: 10146293.
DOI: 10.3390/jcm12082788.
Benefits, harms, and costs of newborn genetic screening for hypertrophic cardiomyopathy: Estimates from the PreEMPT model.
Christensen K, McMahon P, Galbraith L, Yeh J, Stout N, Lu C
Genet Med. 2023; 25(4):100797.
PMID: 36727595
PMC: 10168130.
DOI: 10.1016/j.gim.2023.100797.
Screening for Hypertrophic Obstructive Cardiomyopathy in Patients With Panic Disorder: A Case Report.
Bonitz T, Scypinski L, Chin J, Lomiguen C
Cureus. 2022; 14(11):e31811.
PMID: 36579213
PMC: 9788791.
DOI: 10.7759/cureus.31811.
Barriers and facilitators for the implementation of patient-centered care in cardiogenetics: a Delphi study among ERN GUARD-heart members.
van Pottelberghe S, Heine F, Van Dooren S, Hes F, Kupper N
Eur J Hum Genet. 2022; 31(12):1371-1380.
PMID: 36543931
PMC: 9768771.
DOI: 10.1038/s41431-022-01268-7.
Circulating Biomarkers in Hypertrophic Cardiomyopathy.
Matthia E, Setteducato M, Elzeneini M, Vernace N, Salerno M, Kramer C
J Am Heart Assoc. 2022; 11(23):e027618.
PMID: 36382968
PMC: 9851432.
DOI: 10.1161/JAHA.122.027618.
Case Report: A Chinese Family of Hypertrophic Cardiomyopathy Caused by a Novel Splicing Mutation in the Gene.
Huang C, Zheng Y, Zhang W, Chen Z, Huang Z, Fang Y
Front Genet. 2022; 13:894791.
PMID: 35795207
PMC: 9251305.
DOI: 10.3389/fgene.2022.894791.
Differences in Atrial Remodeling in Hypertrophic Cardiomyopathy Compared to Hypertensive Heart Disease and Athletes' Hearts.
Servatius H, Raab S, Asatryan B, Haeberlin A, Branca M, De Marchi S
J Clin Med. 2022; 11(5).
PMID: 35268407
PMC: 8910879.
DOI: 10.3390/jcm11051316.
Genetic Testing in Patients with Hypertrophic Cardiomyopathy.
Bonaventura J, Polakova E, Vejtasova V, Veselka J
Int J Mol Sci. 2021; 22(19).
PMID: 34638741
PMC: 8509044.
DOI: 10.3390/ijms221910401.
Heritability and Pedigree Analyses of Hypertrophic Cardiomyopathy in Rhesus Macaques ().
Ueda Y, Kovacs S, Reader R, Roberts J, Stern J
Front Vet Sci. 2021; 8:540493.
PMID: 34150876
PMC: 8206789.
DOI: 10.3389/fvets.2021.540493.
Update on Biomarkers Associated to Cardioembolic Stroke: A Narrative Review.
Fonseca A, Coelho P
Life (Basel). 2021; 11(5).
PMID: 34067554
PMC: 8156147.
DOI: 10.3390/life11050448.
Prediction of Genotype Positivity in Patients With Hypertrophic Cardiomyopathy Using Machine Learning.
Liang L, Fifer M, Hasegawa K, Maurer M, Reilly M, Shimada Y
Circ Genom Precis Med. 2021; 14(3):e003259.
PMID: 33890823
PMC: 8206028.
DOI: 10.1161/CIRCGEN.120.003259.
Sex-Related Differences in Protein Expression in Sarcomere Mutation-Positive Hypertrophic Cardiomyopathy.
Schuldt M, Dorsch L, Knol J, Pham T, Schelfhorst T, Piersma S
Front Cardiovasc Med. 2021; 8:612215.
PMID: 33732734
PMC: 7956946.
DOI: 10.3389/fcvm.2021.612215.
Current Knowledge of Hypertrophic Cardiomyopathy Among Health Care Providers in Sweden.
Magnusson P, Morner S
Cureus. 2021; 12(12):e12220.
PMID: 33500852
PMC: 7819499.
DOI: 10.7759/cureus.12220.
Proteomic and Functional Studies Reveal Detyrosinated Tubulin as Treatment Target in Sarcomere Mutation-Induced Hypertrophic Cardiomyopathy.
Schuldt M, Pei J, Harakalova M, Dorsch L, Schlossarek S, Mokry M
Circ Heart Fail. 2021; 14(1):e007022.
PMID: 33430602
PMC: 7819533.
DOI: 10.1161/CIRCHEARTFAILURE.120.007022.
